A few small, visible particles may remain and will be removed by the microaggregate filter.Р”В®ach single-use vial contains approximately 500 mg or 1,000 mg of functionally active alpha-1-proteinase inhibitor. The reconstituted solution should be colorless to slightly yellow to yellowish-green. Reconstitution requires no more than 5 minutes for a 0.5 gram vial and no more than 10 minutes for a 1 gram vial. Do not shake the vial or invert it until ready to withdraw content. Let the vial stand until most of the content is in solution, then gently swirl the vial until the powder is completely dissolved. Remove the diluent vial and the transfer needle. The vacuum in the product vial will draw the diluent into it. Invert the diluent vial, and insert the attached needle into the product vial at an angle, so that the diluent will be directed against the wall of the product to minimize foaming. Remove the cover at the other end of the transfer needle. Remove the cover from one end of the transfer needle, and insert the needle into the diluent vial. The unreconstituted, lyophilized cake should be white or off-white to slightly yellow-green or yellow in color. Have lyophilized drug vial and diluent at room temperature before reconstitution. Findings from the RAPID/RAPID Extension program have confirmed the benefits of A1-PI therapy in slowing disease progression and provided evidence of a disease-modifying effect in patients with AATD the study suggests that the early introduction of treatment may delay the time to death, lung transplantation, or crippling respiratory complaints in patients with emphysema related to severe AATD. Further, clinical data demonstrating long-term effect of therapy are not available. The impact of therapy on pulmonary exacerbations in patients with severe deficiency has not been definitively determined. Alpha-1-proteinase inhibitor (A1-PI) is indicated to treat lung disease only in patients withР’В severe congenital A1-PI deficiency use of the drug in patients without A1-PI deficiency has not been established. If needed for patient comfort or adverse reactions, reduce the infusion rate. For Glassia, infuse at a rate not to exceed 0.2 mL/kg/minute IV. Infuse at a rate of approximately 0.08 mL/kg/minute for Zemaira, Aralast NP, Prolastin, and Prolastin-C. Different brands are infused at different rates.

Maximum action alpha1